Searched for
FDA APPROVAL ZAYNICH
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check detailsWockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections....01 Jun, 2026, 10.11 AM IST- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...01 Jun, 2026, 07.44 AM IST
- Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...31 May, 2026, 05.00 PM IST
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...30 May, 2026, 11.17 PM IST
- Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...28 May, 2026, 09.51 PM IST
- Wockhardt shares jump over 4%, extend two-day rally following FDA nod for ZaynichWockhardt Ltd shares jumped over 4% to ₹1,533, extending a two-day rally after surging nearly 20% on Tuesday. The rise follows the US FDA’s...02 Dec, 2025, 11.35 AM IST
- US FDA review boosts odds for Wockhardt’s NCE success story: Vishal ManchandaWockhardt’s breakthrough respiratory drug Zaynich moves a step closer to market as the US FDA accepts it for review, boosting approval odds...02 Dec, 2025, 09.11 AM IST
- Wockhardt activates Zaynich push, eyes global licensing dealsWockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions ...01 Jul, 2025, 05.11 AM IST
- Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, EuropeWockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europ...05 Jun, 2025, 05.28 PM IST
Load More
